MedTrace Logo

Precision Assessment of Platelet Rich Plasma for Joint Preservation

NCT03460236 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 90

Last updated 2025-05-23

Study results available
· View outcomes & findings →

Summary

Knee Osteoarthritis (OA) is a leading cause of premature disability in Veterans who develop knee OA at higher rates and younger ages than the population in general. For those with symptomatic early knee OA, who are years to decades away from meeting clinical indications for knee replacement surgery, knee injections have been a key treatment option. In recent years, platelet rich plasma (PRP) injections have gained increasing attention for improving pain and function in patients with knee OA. Basic science studies also suggest that PRP may also potentially stimulate repair responses to articular cartilage. However, the mechanisms of action of PRP in the treatment of knee OA are unknown. Because autologous blood is used, the PRP composition differs between patients. It is also unknown whether these differences in PRP composition affect clinical outcomes. This study will address these gaps and provide critical new and objective information on PRP treatment effects in Veterans and additional women with early knee OA important to improving clinical use of this new treatment.

Conditions

Sponsors & Collaborators

  • VA Office of Research and Development

    lead FED

Principal Investigators

  • Constance R. Chu, MD · VA Palo Alto Health Care System, Palo Alto, CA

Eligibility

Min Age
30 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-04-02
Primary Completion
2024-03-29
Completion
2024-03-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03460236 on ClinicalTrials.gov